- Home
- ALHC vs BEAM Comparison
ALHC vs BEAM Comparison
Compare ALHC & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALHC
- BEAM
- Stock Information
- Founded
- ALHC 2013
- BEAM 2017
- Country
- ALHC United States
- BEAM United States
- Employees
- ALHC N/A
- BEAM N/A
- Industry
- ALHC Medical Specialities
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALHC Health Care
- BEAM Health Care
- Exchange
- ALHC Nasdaq
- BEAM Nasdaq
- Market Cap
- ALHC 2.1B
- BEAM 1.9B
- IPO Year
- ALHC 2021
- BEAM 2020
- Fundamental
- Price
- ALHC $11.49
- BEAM $24.05
- Analyst Decision
- ALHC Buy
- BEAM Buy
- Analyst Count
- ALHC 9
- BEAM 11
- Target Price
- ALHC $10.63
- BEAM $45.90
- AVG Volume (30 Days)
- ALHC 2.0M
- BEAM 1.3M
- Earning Date
- ALHC 10-29-2024
- BEAM 11-05-2024
- Dividend Yield
- ALHC N/A
- BEAM N/A
- EPS Growth
- ALHC N/A
- BEAM N/A
- EPS
- ALHC N/A
- BEAM N/A
- Revenue
- ALHC $2,467,707,000.00
- BEAM $349,643,000.00
- Revenue This Year
- ALHC N/A
- BEAM N/A
- Revenue Next Year
- ALHC $29.19
- BEAM $6.04
- P/E Ratio
- ALHC N/A
- BEAM N/A
- Revenue Growth
- ALHC 43.47
- BEAM 328.73
- 52 Week Low
- ALHC $4.46
- BEAM $20.84
- 52 Week High
- ALHC $14.25
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- ALHC 43.08
- BEAM 46.67
- Support Level
- ALHC $12.76
- BEAM $21.46
- Resistance Level
- ALHC $14.20
- BEAM $32.29
- Average True Range (ATR)
- ALHC 0.75
- BEAM 2.04
- MACD
- ALHC -0.13
- BEAM 0.19
- Stochastic Oscillator
- ALHC 18.68
- BEAM 23.92
About ALHC Alignment Healthcare Inc.
Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.